Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Top notch Feasting: A Manual for Worldwide Acclaimed Eateries - 2EU delays signing of Mercosur free trade deal
- 3Top Music and Dance Celebration: Which One Gets You Going?
- 4Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- 5Startled Venezuelans express relief but also fear after Maduro arrest
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- Some super-smart dogs can pick up new words just by eavesdropping
- Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- Improving as a Cook: Culinary Experiences in the Kitchen
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- NATO needs Ukraine's 'adaptation DNA' and an 'HOV lane' for new war tech, top commander says
- Claim that Israel opened 'sewage dam' into Gaza's main river undersells sanitation crisis
- Astounding Treehouses All over the Planet
